Cart
sales@molnova.com
Home - Products - Others - Other Targets - Lirilumab

Lirilumab

CAS No. 1000676-41-4

Lirilumab( —— )

Catalog No. M36889 CAS No. 1000676-41-4

Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 440 In Stock
10MG 692 In Stock
25MG 1026 In Stock
50MG 1376 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Lirilumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.
  • Description
    Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
  • In Vitro
    ——
  • In Vivo
    Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor.Animal Model:Rag1KO-Tg KIR mice injected with tumor cells Dosage:15 mg/kg Administration:intravenous injection; 15 mg/kg; once Result:Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Virus Protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1000676-41-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • SEP-0371845

    SEP-0371845 is a biochemical.

  • Atriopeptin I (rat)

    Atriopeptin I rat, mouse is an atrial natriuretic peptide, which stimulates the testosterone production with half-maximum stimulation of 38 nM.

  • TP0586532

    TP0586532 is effective against carbapenem-resistant Klebsiella pneumoniae and does not pose a cardiovascular risk.

Sign In Join Free